The FDA just put a pause on a cutting-edge gene editing trial that hadn't started yet - and the company's stock is dropping

• The FDA just put a hold on one of the first trials to test the CRISPR gene-editing technology in humans. The trial hadn't begun yet.
• The trial, run by CRISPR Therapeutics and Vertex Pharmaceuticals, plans to look at how the gene-editing technology works to treat patients with sickle cell disease. The trial has been put on hold "pending the resolution of certain questions that will be provided by the FDA."
• CRISPR's stock fell as much as 19% after hours on Wednesday, while Vertex was largely unchanged after-hours.

NOW WATCH: THE KRISTIN LEMKAU INTERVIEW: JPMorgan Chase's CMO explains how she deals with disruption on two fronts at once, why she's moving some ad dollars back to TV, and why it matters what your credit card feels like